"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome
- PMID: 32497346
- DOI: 10.1002/pon.5436
"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome
Abstract
Objective: Genetic testing for hereditary breast and ovarian cancer (HBOC) due to pathogenic variants in BRCA1 or BRCA2 is why most women present to familial cancer centers. Despite being assessed as low risk for HBOC, many women proceed with genetic testing. This study explored the genetic testing experiences of unaffected women at low risk of HBOC to clarify what motivates these women to have testing, and what are the implications of the results.
Methods: A qualitative approach was taken. Participants included women who had genetic testing for HBOC from 2016-2018 at the Parkville Familial Cancer Centre in Melbourne, Australia. In-depth, semi-structured interviews were conducted, and thematic analysis was undertaken on transcripts; transcripts were coded, codes were organized into a hierarchical system of categories/subcategories, and key themes were identified.
Results: Analysis of 19 transcripts identified five themes: family underpinned all motivators for HBOC genetic testing; health professionals were influential throughout the process; participants were planning for a positive result; results influenced screening-anxiety and frequency; and negative results gave participants relief in many different ways. The three participants with positive results reported feeling shocked at the results and empowered giving this information to family members.
Conclusions: Women at low HBOC risk may be motivated to seek genetic testing, and access to this is increasingly offered through non-genetic health professionals. Professionals can support clients through genetic testing by recognizing familial experiences, providing accurate information, addressing risk perceptions, and understanding cancer anxiety felt by many women.
Keywords: BRCA1; BRCA2; cancer; coping; decision making; genetic counselling; genetics; oncology; psychosocial; qualitative.
© 2020 John Wiley & Sons, Ltd.
Similar articles
-
"Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.J Genet Couns. 2018 Aug;27(4):885-893. doi: 10.1007/s10897-018-0214-z. Epub 2018 Feb 5. J Genet Couns. 2018. PMID: 29404823
-
The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.Fam Cancer. 2019 Jan;18(1):127-135. doi: 10.1007/s10689-018-0089-z. Fam Cancer. 2019. PMID: 29846880
-
Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.Fam Cancer. 2024 Jun;23(2):121-132. doi: 10.1007/s10689-024-00379-y. Epub 2024 Apr 25. Fam Cancer. 2024. PMID: 38662264
-
Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.BMJ Open. 2019 Sep 24;9(9):e029926. doi: 10.1136/bmjopen-2019-029926. BMJ Open. 2019. PMID: 31551380 Free PMC article.
-
Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.Cancer. 2022 Jan 1;128(1):94-102. doi: 10.1002/cncr.33866. Epub 2021 Aug 23. Cancer. 2022. PMID: 34424535 Free PMC article.
Cited by
-
Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative.HGG Adv. 2021 Aug 24;3(1):100055. doi: 10.1016/j.xhgg.2021.100055. eCollection 2022 Jan 13. HGG Adv. 2021. PMID: 35047846 Free PMC article.
-
"It Will Lead You to Make Better Decisions about Your Health"-A Focus Group and Survey Study on Women's Attitudes towards Risk-Based Breast Cancer Screening and Personalised Risk Assessments.Curr Oncol. 2022 Nov 25;29(12):9181-9198. doi: 10.3390/curroncol29120719. Curr Oncol. 2022. PMID: 36547133 Free PMC article.
-
Multi-ethnic heterozygote frequencies of cancer susceptibility genes to inform counseling of reproductive risk.Genet Med. 2025 Jan;27(1):101246. doi: 10.1016/j.gim.2024.101246. Epub 2024 Nov 21. Genet Med. 2025. PMID: 39570271
-
Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.Cancers (Basel). 2022 Mar 23;14(7):1636. doi: 10.3390/cancers14071636. Cancers (Basel). 2022. PMID: 35406409 Free PMC article.
-
Impact of barriers and motivators on intention and confidence to undergo hereditary cancer genetic testing.J Genet Couns. 2025 Feb;34(1):e1926. doi: 10.1002/jgc4.1926. Epub 2024 May 27. J Genet Couns. 2025. PMID: 38803214 Free PMC article.
References
REFERENCES
-
- James PA, Mitchell G, Bogwitz M, Lindeman GJ. The Angelina Jolie effect. Med J Aust. 2013;199(10):646.
-
- Liede A, Cai M, Crouter TF, Niepel D, Callaghan F, Evans DG. Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Res Treat. 2018;171(2):435-442.
-
- Jolie A. My medical choice. The New York Times [online]. May 14, 2013 [cited June 08, 2020]. Available from: www.nytimes.com/2013/05/14/opinion/my-medical-choice.html
-
- Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416.
-
- Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol. 2013;230(4):347-349.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous